

Prospective Covid-19 Cohort München KoCo19

- Kooperation Klinikum der LMU und Helmholtz Zentrum München

- InterTB 16.10.2020
- Prof. Dr. Michael Hoelscher

- Michael Pritsch, Inge Kroidl, Laura Olbrich, Jessica Guggenbühl, Andreas Wieser, Elmar Saathoff, Friedrich Rieß, Ahbishek Bakuli, Noemi Castelletti
- Katja Radon, Arbeitsmedizin (KUM)
- Jan Hasenauer, Universität Bonn
- Christiane Fuchs, Universität Bielefeld

Chronology of events



27. Jan 20 Identification of the first SARS-CoV-2 infection in DE at the Tropical Institute in Munich (subsequently 15 cases)

THE NEW ENGLAND JOURNAL of MEDICINE

CORRESPONDENCE



Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany

online: N ENGL J MED JAN 30, 2020

Article

Virological assessment of hospitalized patients with COVID-2019

<https://doi.org/10.1038/s41586-020-2196-x>

Received: 1 March 2020

Accepted: 24 March 2020

Published online: 4 April 2020

Roman Wolfel¹*, Victor M. Corman^{1,2}, Wolfgang Guggemos^{1,2}, Michael Seilmaier³, Sabine Zange⁴, Marcel A. Müller⁵, Daniela Niemeyer⁶, Terry C. Jones^{1,2}, Patrick Vollmar¹, Camilla Rothe¹, Michael Hoelscher¹, Tobias Bleicker¹, Sebastian Brünink¹, Julia Schneider¹, Rosina Ehmann¹, Katrin Zwirgmaier¹, Christian Drosten^{1,2,7} & Clemens Wendtner^{1,2,7}

Nature | Vol 581 | 28 May 2020 | 465

Science

Study claiming new coronavirus can be transmitted by people without symptoms was flawed

By Kai Kupferschmidt | Feb. 3, 2020, 5:30 PM

"No One Here
Thinks It's a Cure"

The New York Times

LEILA EDITOR
"No One Here
Thinks It's a Cure"

VOL. CLXXXI FEB. 23, 2020 NEW YORK, SUNDAY, JUNE 28, 2020 \$15.00

Voters' Moods:
Tired, Anxious
And Optimistic

Battling on the Election
Day

Back a step when
Trump's support
dropped

Cases Soaring
As Leadership
On Virus Fails

How the World Missed
Covid's Symptom-Free Carriers

Back a step when
Trump's support
dropped

Cases Soaring
As Leadership
On Virus Fails

How the World Missed
Covid's Symptom-Free Carriers

Back a step when
Trump's support
dropped

Cases Soaring
As Leadership
On Virus Fails

How the World Missed
Covid's Symptom-Free Carriers

Back a step when
Trump's support
dropped

Cases Soaring
As Leadership
On Virus Fails

How the World Missed
Covid's Symptom-Free Carriers

Back a step when
Trump's support
dropped

Cases Soaring
As Leadership
On Virus Fails


How the World Missed
Covid's Symptom-Free Carriers

Back a step when
Trump's support
dropped

Cases Soaring
As Leadership
On Virus Fails

How the World Missed
Covid's Symptom-Free Carriers

Back a step when
Trump's support
dropped



THE 100 MOST INFLUENTIAL PEOPLE OF 2020

BY BACK TO HOME

Camilla Rothe




KLINIKUM DER UNIVERSITÄT MÜNCHEN®

DEPARTMENT FOR INFECTIOUS DISEASES & TROPICAL MEDICINE


Initial spread of the virus

SARS-CoV-2 introductions to Europe and the US.



Michael Worobey et al. Science 2020

MCC tree of SARS-CoV-2 entry into Europe.




Michael Worobey et al. Science 2020

Science
AAAS


Chronology of events

- 27. Jan 20 Identification of the first SARS-CoV-2 infection in DE at the Tropical Institute in Munich (subsequently 15 cases)
- 02. Mar 20 Next SARS-CoV-2 cases in Munich after Ski-holidays
- 17. Mar 20 Establishment of a drive-through station at the institute




Chronology of events

- 27. Jan 20 Identification of the first SARS-CoV-2 infection in DE at the Tropical Institute in Munich (subsequently 15 cases)
- 02. Mar 20 Next SARS-CoV-2 cases in Munich after Ski-holidays
- 17. Mar 20 Establishment of a drive-through station at the institute
- 19. Mar 20 Concept idea for a population-based study to monitor the effect of social distancing measures
- 20. Mar 20 partial lock-down announced by the Bavarian Government
- 30. Mar 20 Submission of study protocol and temp. approval 2 days later
- 03. Apr 20 Official announcement of the study
- 05. Apr 20 Study start
- 12. Jun 20 Completion of the enrolment of 3.004 households and 5842 household members



KoCo19 Study in context of the newly infected and registered individuals



Start early or later?

- Expected low prevalence and uncertain sensitivity and specificity of serological assays -> positive predictive value very low.
- There was no clear forecast how the epidemic would evolve – so better start early than never.
- Assess data and samples that never can be retrieved anymore.
- Early data are important to refine strategy – an iterative process of learning and improving study concepts on the fly.

It is a long-term project

Challenges

- At the beginning of the pandemic (January - March) all "experts" were busy organizing local emergency aid and informing politicians and the public.
- A coordinated approach between different research groups was practically impossible.
- There were no established scientific networks. Infection epidemiology is a weakly developed field of research in Germany.
- We did not know of similar activities in Germany, Europe or world-wide.
- There were no immediate financial resources available.
- The lack of an established research toolkit (assays) requires until today a high degree of flexibility.
- The pace of scientific knowledge gain is still so high today that the concepts have to be constantly updated.
- **For the first time in the science of history, the project is in the middle of public interest and has become a live documentation.**

The New York Times



By Katrin Bennhold | Photographs by Laetitia Vancon
Published April 18, 2020




Study objectives:

- To describe the SARS-CoV-2 antibody prevalence in the a representative sample of the general population in Munich.
- To understand the proportion of identified versus unrecognized infections.
- In what regards are reognized and unrecognized individuals different (biologically and socioeconomical)
- What is the transmission rate in a household?
- Determine the durability of antibodies after infection.
- Describe the influence do social isolation measures on the incidence?
- To track changes of social behaviour change within the cohort, and what impact does individual behaviour have on the individual risk of infection?
- What is the socio-economic impact of the pandemic and the measures to combat it, in particular on the employment situation and psychological endpoints.


Study design

- Starting points of the random route in 100 of 755 constituencies
- 30 households are selected in each constituency
- Each HH includes all HH members
- For people over 14 years of age 2.7 ml of blood was taken. For children under 14 years of age 300ul was collected from the fingertip. (starting on 15.05)
- Everyone filled out a weekly electronic questionnaire on their state of health
- Repetitions every 12 weeks or according to epidemiological situation



Practical implementation

- Complete look-down
- Had to train 80 medical students in outreach teams of two
- Have enough personal protective equipment
- Rented of fleet of 30 cars
- Support by police to avoid fraud by others
- Did built a complete new serology lab






© Laetia Vancon/The New York Times


KLINIKUM DER UNIVERSITÄT MÜNCHEN®

DEPARTMENT FOR INFECTIOUS DISEASES & TROPICAL MEDICINE

Recruitment:




Validation of 7 assays




Performance of assays

Euroimmun S1 IgG vs Roche N pan-Ig




| Classifier | Specificity Manufacturer | Specificity Optimized | Sensitivity Manufacturer (low) | Sensitivity Manufacturer (high) | Sensitivity Optimized |
|---|-----------------------------|--------------------------|-----------------------------------|------------------------------------|--------------------------|
| Euroimmun S1 IgA (Manufacturer's cut-off) | 0.924 | 0.933 | 0.917 | 1.000 | 0.648 |
| Euroimmun S1 IgA (Optimized cut-off) | | 0.926 | | | 0.648 |
| Euroimmun S1 IgG (Manufacturer's cut-off) | 0.993 | 0.980 | 0.875 | 1.000 | 0.772 |
| Euroimmun S1 IgG (Optimized cut-off) | | 0.978 | | | 0.798 |
| Roche N pan-Ig (Manufacturer's cut-off) | 0.998 | 0.998 | 0.853 | 0.995 | 0.855 |
| Roche N pan-Ig (Optimized cut-off) | | 0.997 | | | 0.886 |

Performance of confirmatory assays



Prevalence

Prevalence adjusted for sensitivity and specificity



1,6% Seroprevalence


vs.

0,4% registered positive PCR cases


Specificity/Sensitivity

- Manufacturer (high sensitivity)
- Manufacturer (low sensitivity)
- Optimized

Seropositivity over time




Next steps?



Follow-up

How much has the proportion of undetected cases has changed since we are testing 4-5 times more?

Fingerprick self-sampling



Automatisation of dried blood serology




Elution of Antibodies




Panthera puncher System

DBS are stable after drying:
Initial experiments compared: 4-7°C, 37°C, -20°C, -80°C
-> for at least 4 days no significant changes in eluted functional Antibodies
-> DBS are stable for extended periods; test now > 4 weeks


Robotic Cup-Transfer



Measurement (qualitative)



KoCo-19 study family



Additional SARS-CoV-2 seroprevalence studies



German National Cohort: longitudinal serosurvey in an existing cohort of 180.000 individuals in 16 regions in Germany (starting in January 2021)



CONNECTING EUROPEAN COHORTS TO INCREASE COMMON AND EFFECTIVE
RESPONSE TO SARS-CoV-2 PANDEMIC: **ORCHESTRA**

KLINIKUM DER UNIVERSITÄT MÜNCHEN®

DEPARTMENT FOR INFECTIOUS DISEASES & TROPICAL MEDICINE

COVID-19 Serosurvey in Africa



Partner

- Jimma University Medical center (JUMC)
- Ludwig-Maximilians-University (LMU) Munich
- Helmholtz Center, Epidemiology


Populations

- Household based survey general population
- Target institutions (health facilities, schools, university, police)

Planned Activities:

- 1-3 monthly serosurveys (dry blood spots)
- eHealth data capture & dissemination (DHIS-2, SORMAS)
- Clinical, socio-economic, ecological, community assessments

Impact of Covid-19 infection on lung function in TB patients



Tanzania

- NIMR-Mbeya Medical Research Center, Mbeya
- Ludwig-Maximilians-University (LMU) Munich

Ethiopia

- Asella Teaching and Referral Hospital
- Heinrich-Heine-University Düsseldorf

Ghana

- Komfo Anokye Teaching Hospital (KATH) , Kumasi,
- University Hospital Hamburg Eppendorf

Rwanda

- Université National du Rwanda, Butare
- Charité – Universitätsmedizin Berlin

Kenya

- Kenyatta National Hospital, University of Nairobi
- Goethe University Frankfurt

Uganda

- Kiruddu National Referral Hospital, Kampala
- University Hospital Leipzig


Studyteam

- Study design: M. Hoelscher, E. Saathoff, K. Radon
- Modelling: J. Hasenauer, C. Fuchs, A. Bakuli, N. Castelletti, F. Theis
- Testing: A. Wieser, R. Wölfel, V. Fingerle, M. Münchhoff, E. Zeggini, C. Geldmacher
- Clinical team: M. Pritsch, I. Kroidl, L. Oblrich, G. Froeschl, V. Thiel, D. Metaxa, C. Rothe
- Data Collection & Management: F. Riess, M. Diefenbach
- Socio-economic analysis: R. Leidl, L. Schwettmann, M. Laxy, S. Prückner
- Project management: J. Guggenbühl, O. Geisenberger, L. Hoffmann, A. Mekota, A. Heiber
- Communication: J. Eckstein
- Field team in alphabetic order: Alexander, Alina, Alisa, Anna, Charlotte, Claire, Clemens, Dafni, Ekaterina, Elias, Elmar, Emma, Eva, Felix, Flora, Friedrich, Friedrich, Hannah, Inge, Isabel, Isabel, Jakob, Jan, Jan, Janna, Jared, Jasmin, Jeni, Jessica, Jonathan, Julia, Julian, Julius, Kerstin, Konstantin, Kristina, Lara, Laura, Laura, Lea, Leonard, Leonie, Magdalena, Marius, Matthias, Max, Maximilian, Michael, Michael, Niklas, Norah, Patrick, Paul, Paula, Philine, Rebecca, Rebecca, Sabine, Silvan, Simon, Sonja, Sophie, Stefan, Stefanie, Thomas, Tim, Tim, Tobias, Ursula, Valeria, Vera, Verena, Vitus

The data analysis team



**Thank you for
your attention**



More information
www.KoCo19.de